NCT04528355RECRUITINGanonymous

A Prospective Outcomes Study of Pediatric and Adult Patients With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation With a Reduced-Intensity Conditioning Regimen (PRO-RIC)

Sponsor

Source record

Paul Szabolcs

Phase

Source record

Not classified

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

data collection

Indication / condition

AI-normalized

Primary Immunodeficiency (PID)

Intervention

Source record

data collection

Related intelligence directories

Indication directory: Primary Immunodeficiency (PID)Modality directory: monoclonal antibody Target directory: data collection

Source & freshness

Source record

NCT ID

NCT04528355

Original source

ClinicalTrials.gov

Source last updated

Jan 13, 2026

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04528355

Title

A Prospective Outcomes Study of Pediatric and Adult Patients With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation With a Reduced-Intensity Conditioning Regimen (PRO-RIC)

Sponsor

Paul Szabolcs

Status

RECRUITING

Phase

Detailed source ingestion pending

Condition raw

Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions

Condition normalized

Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

data collection

Target normalized

data collection

Interventions

data collection

Public preview

Source record

This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective Outcomes Study of Pediatric and Adult Patients With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation With a Reduced-Intensity Conditioning Regimen (PRO-RIC)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT04528355

Status

RECRUITING

Phase

N/A

Sponsor

Paul Szabolcs

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 13, 2026

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04528355

Indication

Primary Immunodeficiency (PID)

Modality

monoclonal antibody

Target

data collection

Intervention

data collection

Source record